

## **Initial experience with short-course corticosteroids in a small cohort of adults with severe COVID-19 in a tertiary care hospital in India**

Sanjiv Jha\*, Kiran Shetty\*, Sonali Vadi\*, Sourabh Phadtare\*, Vatsal Kothari\*, Abhijit Raut&, Sweta Shah#, Pallavi Bhargava@, Tanu Singhal^

\*Department of Critical Care Medicine

&Department of Radiology

#Department of Microbiology

^ Department of Infectious Disease

Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India

@ Department of Internal Medicine, Division of Infectious Disease, Detroit and WestBloomfield Hospital, Michigan, USA

### **Abstract**

Severe COVID 19 disease is associated with high morbidity and mortality with limited therapeutic options. The role of glucocorticoids in treatment of COVID 19 has been riddled with controversy. The study site has been using glucocorticoids in patients with severe COVID 19 since the first few patients of COVID 19 that were admitted. In the initial cohort of 7 patients with severe COVID disease, use of methylprednisolone in a dose of 30 mg twice daily was associated with rapid improvement in oxygenation and decline in CRP levels. While six patients made a complete clinical recovery, one patient died. There were no secondary infections.

India is in the midst of the COVID-19 epidemic with steady rise in the numbers of cases and deaths (1). In Mumbai, one of the epicentres of the outbreak several private hospitals have set up COVID treatment units. The study site has set up a negative pressure 17 bed COVID-19 unit since 23rd March 2020. The infection prevention, admission and treatment protocols are in line with recommendations from Government of India (2). Severe COVID 19 is associated with high morbidity and mortality. Treatment options are limited. There has been a controversy about the benefit of steroids in severe COVID 19. We describe here our experience in managing our first few severe cases of COVID-19 with glucocorticoids over a 2 weeks period between 26<sup>th</sup> March and 8<sup>th</sup> April 2020. The Institutional Research and Ethics Committee granted a waiver of review for the study.

Eighteen adults with a confirmed diagnosis of COVID-19 by RT-PCR were admitted to the unit in the study period. Of these seven were having severe disease (defined as oxygen saturation  $\leq 93\%$  at any time during the hospital stay), 10 had mild symptoms and one was asymptomatic. Further discussion is confined to the seven patients with severe disease (Table 1). Five were male and the mean age was 58 years (range 44-70 years). Four patients had comorbidities including hypertension (3), diabetes mellitus (2), chronic kidney disease (1) and obstructive airway disease (1). The mean duration of symptoms prior to admission was 7 days (range 4-10 days). Fever, cough and breathing difficulty were present in all patients; one patient had gastrointestinal symptoms of diarrhoea and vomiting. Three were febrile, all had tachycardia but none had hypotension. Five patients were tachypneic and hypoxic at admission while two patients (1 and 6, Table 1) developed hypoxia on day 4 and day 3 of hospitalization. The investigative profile of the study patients at admission is summarized in Table 2. Blood cultures sent at admission were negative in all patients. In the 5 patients who

were hypoxic on admission, radiologic investigations were carried out and were abnormal (CXR in 3, CT in 1 and both CXR and CT in 1). The CT scans showed the classic findings of bilateral peripheral consolidations and ground glass opacities. The two patients (1 and 6, Table 1) who became hypoxic later on day 4 and day 3 respectively had abnormal CXR on the day of deterioration.

As per institutional protocol all these patients were initiated on parenteral antibiotics (ceftriaxone in 6 and piperacillin tazobactam in 1), azithromycin, hydroxychloroquine (400 mg twice daily on day 1 and then 200 mg twice daily), low molecular weight heparin and vitamin C. Intravenous fluids were given as per requirement. Respiratory support during hospitalization included oxygen by nasal prongs/ non rebreathing mask in 4 patients, non invasive ventilation in one and mechanical ventilation (MV) in 2 patients.

The treatment protocol was modified on 30<sup>th</sup> March 2020 to include corticosteroids after telephonic discussion with a member of the Henry Ford COVID 19 management task force at Detroit, Michigan, USA based on the encouraging results seen by their team with use of intravenous methylprednisolone 30 mg twice daily for 3 days in hospitalized COVID 19 patients. All 7 study patients thus received intravenous methyl prednisolone in a dose of 30 mg twice daily either at admission (patients 3,5) or when they became hypoxic (patients 1 and 6) or when they did not improve with conventional therapy (2,4,7). The response to therapy was monitored by change in clinical parameters including fever, oxygen saturation, requirement of respiratory support and CRP levels. Over the next few days, there was a significant decline in inflammatory markers including CRP, improvement in CXR and reduction of oxygen requirements (Table 1). Steroids were discontinued after 3 days in 6 patients but continued for 7 days in one patient (no 7) who had prolonged hypoxia (Table 1). Tocilizumab was used in 2 patients. In patient no 1, who had persistent fever, rising CRP and who

developed hypoxia on day 4, two doses of tocilizumab 400 mg were given first followed by steroids. In patient number 6 a single dose of tocilizumab 400 mg was given 48 hours after initiation of steroids in view of high IL-6 levels and declining but persistently elevated CRP. One patient (No 2) who showed improvement in the ventilation parameters and CXR and decline in CRP after initiation of steroid therapy died suddenly on day 6 following bradycardia and cardiac arrest). Of the other 6 patients, 4 have been discharged home and 2 are in hospital on room air. As per ICMR and state protocol patients can be discharged only when two successive nasopharyngeal swabs turn negative (2). The mean duration of respiratory support required by the study patients was 6 days (range 5-8 days), mean duration to achieve nasopharyngeal swab negativity was 10 days (range 5-12 days) and mean hospital stay in discharged patients 11 days (range 6-13 days). None of the patients developed clinical or culture proven sepsis during the hospital stay.

It is well established that the cytokine storm with excess production of various interleukins (IL1 IL2, IL6, IL7, IL10), GCSF, and TNF $\alpha$  is central to the pathogenesis of COVID-19. Hence it is proposed that use of immunomodulatory therapy including corticosteroids and IL6 inhibitors such as tocilizumab could prove useful (3,4). The literature till some time ago was divided about the benefit of steroids in COVID-19. Most of the international guidelines recommended against use of steroids owing to previous lack of efficacy in severe acute respiratory syndrome (SARS), MERS (Middle East Respiratory syndrome) and pandemic influenza, risk of super infections and increased viral shedding (4,5,6). On the other hand, Chinese experts recommended using low to moderate dose steroids for 5-7 days in patients with moderate to severe ARDS due to COVID 19 (7). A recently published single pre-test, single post-test quasi-experiment by the Henry Ford COVID-19 management task force (on whose advice we started using corticosteroids) have reported significant impact of early short course methyl prednisolone on clinical outcomes, length of stay and mortality in patients

with moderate to severe COVID-19 (8). Very recently the recovery trial from the UK reported mortality benefit with use of dexamethasone 6 mg once daily for 10 days (9).

While ours is a small cohort, we have replicated the results from the previous studies in Indian patients. We have also demonstrated good results with methylprednisolone as against dexamethasone used in the Recovery trial. The strength of the study lies in precise documentation of the clinical/ radiologic course and investigative work up of the patients. The limitations of the study include its small sample size, observational nature, single centre experience, absence of a control group and use of other interventions (respiratory support and tocilizumab) which may have contributed to clinical improvement. Also clinicians should remember that patients with COVID 19 can have respiratory deterioration due to a variety of reasons including pulmonary thromboembolism, myocarditis, evolving fibrosis and bacterial infections which will not improve/ may worsen with steroids. Hence careful selection of patients, close monitoring and good supportive care is essential when steroids are administered in COVID 19.

### **Funding**

None

### **Conflicts of Interest**

None

### **References**

1. COVID 19 dashboard. Available at <https://www.mygov.in/covid-19>. Accessed on April 12, 2020.
2. Revised Guidelines on Clinical Management of COVID – 19. Available at <https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf>. Accessed on April 12,2020.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506.
4. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). *Crit Care Med*. 2020;10.1097/CCM.0000000000004363. doi:10.1097/CCM.0000000000004363
5. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. 2020;395:473–475.
6. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection. Available at <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>. Accessed April 12,2020.
7. Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M et al. Expert Consensus on the Use of Corticosteroid in Patients With 2019-nCoV Pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020; 43[0]:E007.

8. Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. *Clin Infect Dis*. 2020;ciaa601. doi:10.1093/cid/ciaa601.
9. Randomized evaluation of COVID -19 therapy (Recovery). Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Available at [www.recoverytrial.net/news/](http://www.recoverytrial.net/news/). Accessed on June 23,2020

Table 1: Clinical course of the study patients

SN	Patient details	Days of hospitalization													
		0	1	2	3	4	5	6	7	8	9	10	11	12	13
1	55 M, HTN	High Fever, Saturation 97% on room air CRP 210 mg/l			Sat 91% O <sub>2</sub> 2l Toci CRP 290mg/l IL6 124 pg/ml	O <sub>2</sub> Sat 95% Toci Steroids	O <sub>2</sub> requirements stable Sat 97% CRP 180 mg/l No fever			Asymptomatic			D/C		
2	58 M, Obese	Fever, Sat 92% O <sub>2</sub> started CRP 160 mg/l	ET MV CRP 310 mg/l	Steroids Stable ventilator settings, Sat 96% CXR better CRP declined successively to 250 and then 100 mg/l			Bradycardia Cardiac arrest CRP 40mg/l								
3	55 F, OAD	Saturation 91% on RA at presentation Non invasive ventilation Steroids for 3 days CRP declined from 30 mg/l to 8 mg/l, Sat 96%						Off non invasive ventilation and oxygen					D/C		
4	44 F	Febrile Saturation 91% on RA O <sub>2</sub> 6 liters/min CRP 90mg/l	Steroids Sat 96%, decline in O <sub>2</sub> requirement Decline in CRP to 30 mg/l				Off O <sub>2</sub> asymptomatic					D/C			
5	55 M	Saturation 90% on RA Fever O <sub>2</sub> 4l, awake proning CRP 127 mg/l		Sat 95%, Decline in O <sub>2</sub> requirements Decline in CRP to 90 and then 14 mg/l			Off O <sub>2</sub> Asymptomatic CRP 3 mg/l					D/C			
6	70 M DM, HT, CKD	Asymptomatic Saturation 95% on RA CRP 30 mg/l		Fever CRP 300	MV Steroid CRP	MV Steroid CRP	MV Tapering inotropes		Extubated	O <sub>2</sub> CRP 3 mg/l	O <sub>2</sub> stopped	Asymptomatic waiting for nasal swab to turn			



			mg/l ET, MV Steroid s	410	200 IL-6 55pg/ ml Toci	CRP 90 mg/l and then 30 mg/l				negative
7	47 M DM, HT	Saturation 88% on RA at presentation O <sub>2</sub> 8 l/min CRP290 mg/l	Steroids O <sub>2</sub> requirements declining, Sat 95% Decrease in CRP from 270 mg/l to 13 mg/l			Asymptomatic, on RA waiting for NP swab to turn negative				

M: Male, F: Female, HTN: Hypertension, DM: diabetes mellitus, OAD: obstructive airway disease, CRP: C reactive protein, Toci: Tocilizumab, D/C: discharged, RA: room air, NIV: Non invasive ventilation, CKD: chronic kidney disease, ET: endotracheal intubation, MV: mechanical ventilation, NP: nasopharyngeal, Ino: Inotropes`

Table 2: Investigations of study patients at admission

	<b>Absolute lymphocyte count/ mm<sup>3</sup></b>	<b>ANC: ALC</b>	<b>Platelet count/mm<sup>3</sup></b>	<b>CRP mg/l</b>	<b>PCT ng/ml</b>	<b>Creatinine mg/dl</b>	<b>AST/ALT IU/l</b>	<b>LDH mg/l</b>	<b>CPK IU/l</b>	<b>D Dimer</b>	<b>Ferritin ng/ml</b>
Abnormal defined as	<1000	>3.5	<150,000	>6	>0.5	>1.4	>80/100	>225	>171	>500	>274
Patient 1	1100	2.45	137,000	210	0.2	1.04	28/34	248	110	881	-
Patient 2	500	21	255,000	160	1.91	1.08	24/21	496	327	643	-
Patient 3	1400	4	331,000	30	0.3	1.38	46/16	304	104	1335	90
Patient 4	1400	2.85	223,000	90	0.24	0.61	184/160	715	69	-	-
Patient 5	1100	4	259,000	127	91.6	0.86	34/32	306	140	804	339
Patient 6	1800	3.3	187,000	30	0.1	1.83	36/26	310	185	579	-
Patient 7	700	6.28	358,000	290	0.69	1.6	71/55	427	143	2006	715
<b>Abnormal</b>	<b>3/7</b>	<b>4/7</b>	<b>1/7</b>	<b>7/7</b>	<b>3/7</b>	<b>2/7</b>	<b>1/7</b>	<b>7/7</b>	<b>3/7</b>	<b>6/6</b>	<b>2/3</b>